H.C. Wainwright raised the firm’s price target on Entrada Therapeutics (TRDA) to $20 from $18 and keeps a Buy rating on the shares following the Q3 report. The company has two candidates approaching mid-stage clinical trial entry, the analyst tells investors in a research note.